NEW YORK (GenomeWeb) – Cancer Genetics and Mendel Health announced today that they have formed a strategic alliance to combine their respective cancer clinical trial matching platforms.
Under the terms of the deal, the companies will incorporate Mendel's deep-learning engine — called Mendel.ai — in CGI's disease-focused reports and testing results. An initial version of the system is expected to be available to early-access partners in the second quarter of this year, with a wider rollout later in 2017, they said.
Additional terms were not disclosed.
"By integrating Mendel's proprietary AI technology, CGI is the first diagnostic company able to augment the oncologist's decision making by continuously matching the patient's data with emerging clinical trials based on previous diagnostic tests and any shared clinical data or records," Mendel Health Founder and CEO Karim Galil said in a statement.
"By incorporating our state-of-the art genomic and biomarker reports and data with the ability to integrate real-time clinical trial matching and available health information, we can change patient lives, change outcome curves at cancer centers, and improve the major gaps in oncology patient recruitment," CGI President and CEO Panna Sharma added.